Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

2.1K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.1K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

792
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
792
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

6.2K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
6.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.3K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.3K
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

777
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
777

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consultation report - gonococcal immunoassays and standards for vaccine development.

Vaccine·2026
Same author

Estimating the potential number of cases prevented by infant/ toddler immunisation with a MenACWY vaccine.

Vaccine·2024
Same author

A novel likely pathogenic CLCN5 variant in Dent's disease.

BMC nephrology·2023
Same author

Vaccination, information and parental confidence in the digital age in England.

Vaccine: X·2023
Same author

B-cell depletion abrogates immune mediated cytopenia and rejection of cord blood transplantation in Hurler syndrome.

Bone marrow transplantation·2021
Same author

Sampling implications of variation in daily activity of the sheep tick, Ixodes ricinus at a coastal grassland site in the U.K.

Medical and veterinary entomology·2021

Related Experiment Video

Updated: Nov 2, 2025

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles
09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles

Published on: March 18, 2015

11.8K

Colchicine inhibits ROS generation in response to glycoprotein VI stimulation.

G J Pennings1,2, C J Reddel3,4, M Traini3,4

  • 1The ANZAC Research Institute, Concord Repatriation General Hospital, Hospital Road, Concord, NSW, 2139, Australia. gpennings@anzac.edu.au.

Scientific Reports
|June 8, 2021
PubMed
Summary

Colchicine reduces platelet aggregation and reactive oxygen species generation, potentially explaining its cardiovascular benefits. This study uncovers specific anti-platelet mechanisms involving the GPVI receptor pathway.

More Related Videos

Visualization of Vascular Ca2+ Signaling Triggered by Paracrine Derived ROS
07:33

Visualization of Vascular Ca2+ Signaling Triggered by Paracrine Derived ROS

Published on: December 21, 2011

15.7K
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.1K

Related Experiment Videos

Last Updated: Nov 2, 2025

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles
09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles

Published on: March 18, 2015

11.8K
Visualization of Vascular Ca2+ Signaling Triggered by Paracrine Derived ROS
07:33

Visualization of Vascular Ca2+ Signaling Triggered by Paracrine Derived ROS

Published on: December 21, 2011

15.7K
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.1K

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Hematology

Background:

  • Colchicine is known to reduce cardiovascular events in coronary artery disease (CAD) patients.
  • Its anti-inflammatory properties are established, but mechanisms of action on platelets are not fully understood.

Purpose of the Study:

  • To investigate colchicine's effects on platelet activation pathways.
  • Focus on collagen glycoprotein (GP)VI receptor, P2Y12 receptor, and procoagulant platelet formation.

Main Methods:

  • In vitro studies using whole blood and platelet-rich plasma.
  • Multiplate aggregometry and flow cytometry were employed.
  • Assessed platelet aggregation, reactive oxygen species (ROS) generation, P-selectin expression, GPIIb/IIIa conformational change, and procoagulant platelet formation.

Main Results:

  • Therapeutic colchicine concentrations decreased platelet aggregation and ROS generation in response to collagen and GPVI stimulation.
  • Higher concentrations inhibited P-selectin expression, GPIIb/IIIa change, and procoagulant platelet formation.
  • Low concentrations modulated the GPVI receptor pathway.

Conclusions:

  • Colchicine exhibits anti-platelet effects through multiple pathways.
  • Modulation of the GPVI receptor pathway at low concentrations may contribute to colchicine's protective role in CAD.